Verano HoldingsVRNOD +0.19%65 EBITDA Margin % is 18.40% as of Mar. 2026, which is 36% above its 10-year median of 13.55. GuruFocus rates VRNOD with a GF Score™ of 65/100 and a GF Value™ of $7.76 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Verano Holdings ranks worse than 78.43% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Verano Holdings's EBITDA for the
three
months ended in Mar. 2026 was $38.3 Mil. Verano Holdings's Revenue for the
three
months ended in Mar. 2026 was $208.2 Mil. Therefore, Verano Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 18.40%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Verano Holdings EBITDA Margin % Related Terms
Verano Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Verano Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Verano Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verano Holdings EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Verano Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Verano Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verano Holdings (VRNOD) has a EBITDA Margin % of 18.40% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Verano Holdings and its competitors. This is 36% above median its historical median of 13.55. According to the industry distribution chart, Verano Holdings ranks #749 out of 955 companies in the Drug Manufacturers industry, placing it in the top 78.4%.
Is Verano Holdings' EBITDA Margin % too high?
Verano Holdings' current EBITDA Margin % of 18.40% is 36% above median its 10-year median of 13.55. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Verano Holdings' value of 18.40% is 48.5% above this industry median. Based on the distribution chart, Verano Holdings ranks #749 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Verano Holdings has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Verano Holdings' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Verano Holdings ranks #749 out of 955 companies for EBITDA Margin %. This places Verano Holdings in the lower half of its industry. The industry median EBITDA Margin % is 12.39. Verano Holdings' value of 18.40% is 48.5% above this benchmark. While the company's 10-year median is 13.55 vs. the industry median of 12.39, Verano Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verano Holdings's current EBITDA Margin % of 18.40% is 48.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Verano Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verano Holdings's current EBITDA Margin % is 18.40%, which is 36% above median its own 10-year median of 13.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verano Holdings stock overvalued right now?
Based on GuruFocus' analysis, Verano Holdings (VRNOD) is currently considered Possible Value Trap. The stock's GF Value™ is $7.76, compared to a current price of $5.31 — trading 31.6% below its estimated fair value. The current EBITDA Margin % is 18.40%, which is 36% above median its 10-year median of 13.55 and 48.5% above the Drug Manufacturers industry median of 12.39. Verano Holdings' overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Verano Holdings (VRNOD), the current EBITDA Margin % is 18.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Verano Holdings (VRNOD) Overvalued in 2026?
Based on GuruFocus' analysis, Verano Holdings stock appears to be undervalued.
The current stock price of $5.31 is trading 31.6% below its estimated GF Value™ of $7.76.
GuruFocus considers Verano Holdings to be Possible Value Trap.
Key valuation signals for VRNOD:
EBITDA Margin %: 18.40% (36% above median its 10-year median of 13.55)
GF Value™: $7.76 vs. price of $5.31 (31.6% below fair value)
Industry Position: 48.5% above the Drug Manufacturers median (#749 of 955)
No single metric tells the full story. See the VRNOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Verano Holdings Corp is a vertically integrated, multi-state cannabis operator in the United States. The company operates through cultivation (wholesale) and retail segments. Its consumer brands include Encore, Avexia, MUV, Savvy, BITS, and Verano, while its retail dispensaries operate under brands such as Zen Leaf and MUV. The company derives the majority of its revenue from the retail segment.
65GF Score
Get the complete analysis for VRNOD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRNOD has been successfully added to your 
